Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02060

Immunotherapy in People with HIV and Cancer

Camille E. Puronen1, Emily S. Ford2 and  Thomas S. Uldrick2*
  • 1University of Washington, United States
  • 2Fred Hutchinson Cancer Research Center, United States

HIV infection increases the risk of cancer. HIV-associated lymphocytopenia and immune dysregulation permit immune evasion of oncogenic viruses and premalignant lesions. Various types of immunotherapy, including monoclonal antibodies, interferon, cytokines, immunomodulatory drugs (IMiDs), allogeneic hematopoietic stem cell transplant, and most importantly ART have shown efficacy in HIV-related cancer. Emerging data suggest that checkpoint inhibitors targeting the PD-1/PD-L1 pathway can be safe and effective in people with HIV and cancer. Cancer immunotherapies may also affect HIV latency reversal, HIV-specific immunity, and the viral reservoir. Studying immunotherapy in people with HIV and cancer presents a unique opportunity to gain insight into mechanisms for HIV eradication.

Keywords: HIV, Immunotherapy, HIV reservoir, Cancer, PD-1, Kaposi sarcoma, Lymphoma

Received: 15 May 2019; Accepted: 15 Aug 2019.

Copyright: © 2019 Puronen, Ford and Uldrick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. Thomas S. Uldrick, Fred Hutchinson Cancer Research Center, Seattle, 19024, Washington, United States, tuldrick@fredhutch.org